India's Draft Biotech Patent Guidelines: What U.S. Applicants Should Know Now

India's Patent Office has published the Draft Guidelines for Examination of Patent Applications in the Field of Biotechnology, 2026, replacing guidance that dates back to 2013. The draft brings 13 years of statutory amendments, administrative directives, and case law into day-to-day examination practice. For U.S. filers, the stakes are concrete: claims drafted for the USPTO will now be tested against India's distinct rules on diagnostics, efficacy, enablement, and disclosure. Those rules can reward some U.S.-style claims and sink others. Because the draft limits claim amendments to disclaimers, corrections, or explanations, the claim set and supporting data that enter India in the Patent Cooperation Treaty (PCT) national phase largely set the ceiling on what can be obtained. That makes the period before national-phase entry the critical moment to restructure claims for India: lead with kit and device claims where diagnostic method claims face risk, line up comparative efficacy data